Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Free Cash Flow (2016 - 2025)

Capricor Therapeutics has reported Free Cash Flow over the past 15 years, most recently at -$25.2 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$25.2 million for Q4 2025, down 65.07% from a year ago — trailing twelve months through Dec 2025 was -$72.7 million (down 76.65% YoY), and the annual figure for FY2025 was -$72.7 million, down 76.65%.
  • Free Cash Flow for Q4 2025 was -$25.2 million at Capricor Therapeutics, down from -$19.7 million in the prior quarter.
  • Over the last five years, Free Cash Flow for CAPR hit a ceiling of $23.5 million in Q1 2022 and a floor of -$25.2 million in Q4 2025.
  • Median Free Cash Flow over the past 5 years was -$7.5 million (2022), compared with a mean of -$7.8 million.
  • Biggest five-year swings in Free Cash Flow: surged 797.47% in 2022 and later crashed 290.49% in 2025.
  • Capricor Therapeutics' Free Cash Flow stood at -$6.0 million in 2021, then decreased by 26.68% to -$7.6 million in 2022, then tumbled by 59.99% to -$12.2 million in 2023, then decreased by 25.78% to -$15.3 million in 2024, then tumbled by 65.07% to -$25.2 million in 2025.
  • The last three reported values for Free Cash Flow were -$25.2 million (Q4 2025), -$19.7 million (Q3 2025), and -$20.4 million (Q2 2025) per Business Quant data.